<DOC>
	<DOC>NCT01288963</DOC>
	<brief_summary>The purpose of this study is to determine which participants with melanoma have a better response to IL-2 and to identify markers that may predict response to IL-2 by collecting participant information (for example; cancer diagnosis and history, prior treatments for cancer, etc.) blood and tumor samples prior to treatment and tumor measurements after treatment.</brief_summary>
	<brief_title>IL-2 "SELECT" Tissue Collection Protocol in Patients With Advanced Melanoma</brief_title>
	<detailed_description>Original tumor slides will be collected to identify tumor markers that may predict responses to treatment. Blood samples will be obtained prior to treatment with IL-2.</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Aldesleukin</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<criteria>Malignant melanoma that is metastatic or unresectable Eligible to receive highdose IL2 Tissue block available with adequate tumor to perform RNA extraction and DASL analysis Prior immunotherapy for unresectable or metastatic disease Untreated brain metastases, leptomeningeal disease, or seizure disorder</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>melanoma</keyword>
	<keyword>IL-2</keyword>
	<keyword>Aldesleukin</keyword>
</DOC>